Equinox leans into GLP‑1 users
Gyms and lifestyle brands are treating GLP‑1 weight‑loss drugs as an opportunity, and Equinox has launched a training and lifestyle program specifically tied to the trend — signaling that gyms expect clients to pair medication with structured fitness. (businessinsider.com).
Equinox is treating weight-loss drugs less like a medical side note and more like a new member category. Business Insider reported on April 11 that the company has launched a training and lifestyle program for people using glucagon-like peptide-1 drugs, the class behind Wegovy and similar treatments. (businessinsider.com) That move tells you how gyms now see the boom: not as competition, but as demand for coaching. Equinox had already published a January 2024 article telling members on Ozempic that “you need a strategy” and describing a research-backed protocol built around training, nutrition, and recovery. (equinox.com) The drugs work by making people feel fuller and eat less, but the official label was never “take the shot and do nothing else.” The Food and Drug Administration says Wegovy should be used with a reduced-calorie diet and increased physical activity, and it says the same for Zepbound. (fda.gov 1) (fda.gov 2) That creates an opening for any company that can sell the “everything around the drug.” Mayo Clinic says weight-loss medication is not a substitute for diet and exercise and now offers its own companion support program for people using these medicines. (mayoclinic.org) The fitness pitch is not just “burn more calories.” Equinox’s own explanation focuses on preserving muscle and avoiding drops in physical performance while people lose weight on glucagon-like peptide-1 drugs. (equinox.com) That concern is grounded in the medical literature. A recent review in the National Library of Medicine says glucagon-like peptide-1 drug weight loss can average roughly 15% to 25% after about a year, but it also points to known risks and growing attention to muscle loss and what happens when patients stop treatment. (pmc.ncbi.nlm.nih.gov) Equinox is not building this around bargain pricing. Business Insider says its memberships cost more than $200 a month, and one user it interviewed said he pays $400 a month for three weekly sessions with a personal trainer after starting the medication. (businessinsider.com) The broader market is moving the same way at every price point. Business Insider says Planet Fitness, which charges about $15 a month, is also publishing exercise advice for people on these drugs, which means the trend has spread from luxury gyms to mass-market chains. (businessinsider.com) The reason brands are reorganizing around this is scale. A J.P. Morgan projection cited by Markets Insider says about 10 million Americans were on glucagon-like peptide-1 treatment in 2025 and that figure could reach 25 million by 2030. (markets.businessinsider.com) Once that many people are changing how they eat, train, shop, and size their clothes, the winners are not just drugmakers like Novo Nordisk and Eli Lilly. Equinox is betting that the next layer of money sits in the routine around the prescription: workouts, coaching, nutrition plans, recovery, and a monthly membership that promises to turn fast weight loss into something that looks intentional. (businessinsider.com) (equinox.com)
